Data Bytes: COVID-19 pipeline still growing

BioCentury is providing this content for free given the urgent need for information about the coronavirus crisis. Further analysis can be found in our COVID-19 Resource Center. For more, sign up for our daily email.

Last week saw at least 17 new programs added to the COVID-19 pipeline, bringing the total number of candidates BioCentury is tracking in its COVID-19 Resource Center to 679.

Among the 12 new therapeutic entrants to the clinic are a pair of candidates aimed at decreasing lung damage: the oral HIF-PH inhibitor Vafseo from Akebia Therapeutics Inc. (NASDAQ:AKBA) and the NK1R antagonist Cinvanti from Heron Therapeutics Inc. (NASDAQ:HRTX). Both programs are in Phase II testing.

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers